Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06597292

The VIS Opti-K Low Vision Aid Device Provides Vision Improvement.

The VIS Opti-K Low Vision Aid device will be used to provide vision improvement to patients with refractive disorders (hyperopia and presbyopia).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Clarity Eye Institute, Toronto, Ontario, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects who meet all of the following criteria are candidates for this study:

  • Male or Female
  • Any race
  • Patient is at least 40 years old.
  • Patient is pseudophakic or is phakic with no clinically significant cataract in eye(s) to be treated.
  • Patient has manifest refraction, spherical equivalent (MRSE) between -0.50 D to 2.50 D, with no more than 1.0 D of refractive cylinder, in eye(s) to be treated.
  • Patient has uncorrected distance visual acuity (UDVA) of 20/100 or better (i.e., LogMAR ≤ 0.70) in both eyes.
  • Patient has best corrected distance visual acuity (CDVA) of 20/20 or better (i.e., LogMAR ≤ 0.00) in both eyes.
  • Patient has uncorrected near visual acuity (UNVA) between 20/50 (LogMAR 0.40) and better than 20/100 (LogMAR < 0.70) in eye(s) to be treated.
  • Patient has best corrected near visual acuity (CNVA) of at least 20/20 (LogMAR ≤ 0.00) in eye(s) to be treated.
  • Patient requires reading adds of +1.0 to +3.0 D in eye(s) to be treated.
  • Patient is not a contact lens (CL) wearer.
  • Patient has normal corneal topography.
  • Patient is willing and able to comply with all examinations.
  • Patient must be competent to sign an informed consent form before study entry.

Exclusion criteria

Subjects who meet any of the following criteria are to be excluded from this study:

  • Corneal disease or corneal disorder in either eye.
  • Any active ocular surface disease of any severity.
  • Increased IOP (above 20 mm Hg), glaucoma or history of glaucoma.
  • Previous corneal surgery in the eye to be treated.
  • Conjunctivochalasis
  • Nystagnus
  • Diabetes
  • Pregnancy
  • Presence or history of any other condition or finding that, in the opinion of the investigator, makes the patient unsuitable as a candidate for study participation or that may confound the outcome of the study.

nclusion Criteria: -

Exclusion criteria

-

Treatment and study plan

Vision improvement

Device

Vision improvement for patients with refractive disorders (hyperopia and presbyopia)

Primary outcomes

  1. Uncorrected Distance Visual Acuity (UDVA)

    Time frame: Up to 24 months post-treatment

    Uncorrected distance visual acuity (UDVA) is to be measured and reported using standard ETDRS visual acuity charts. UDVA change from baseline is also to be reported.

  2. Uncorrected Near Visual Acuity (UNVA)

    Time frame: Up to 24 months post-treatment

    Uncorrected near visual acuity (UNVA) is to be measured and reported using standard near visual acuity charts. UNVA change from baseline is also to be reported.

Study contacts

Contact information is provided by the study sponsor or research team.

Harry Glen, MD

CONTACT

[email protected]

561-252-0946

Michael Berry, PhD

CONTACT

[email protected]

8318691384

Sponsors and collaborators

Lead sponsor

VIS, Inc.

Industry

Registry information

Official study title

Vision Improvement for Patients With Presbyopia

Acronym: Opti-K Pres

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Sep 19, 2024
Registry last updated
Sep 25, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.